These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 22101450)

  • 61. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Levosimendan: a new option in acute cardiac failure.
    Holley AD; Ziegenfuss M
    Emerg Med Australas; 2006; 18(5-6):505-9. PubMed ID: 17083641
    [No Abstract]   [Full Text] [Related]  

  • 63. Use of pimobendan in feline congenital heart failure.
    Wainberg S
    Can Vet J; 2013 Dec; 54(12):1164-6. PubMed ID: 24293678
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure.
    Perrone SV; Kaplinsky EJ
    Int J Cardiol; 2005 Sep; 103(3):248-55. PubMed ID: 16098385
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Levosimendan: implications for clinicians.
    McBride BF; White CM
    J Clin Pharmacol; 2003 Oct; 43(10):1071-81. PubMed ID: 14517189
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure.
    Kota B; Prasad AS; Economides C; Singh BN
    J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):269-78. PubMed ID: 19087950
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Acute and long-term hemodynamic effects of pimobendan (UD-CG 115 BS) in comparison with captopril.
    Hauf GF; Grom E; Jähnchen E; Roskamm H
    J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S49-56. PubMed ID: 2478793
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The role of novel inotropic agents in the treatment of heart failure.
    LeJemtel TH; Keren G; Reis D; Sonnenblick EH
    J Cardiovasc Pharmacol; 1986; 8 Suppl 9():S47-54. PubMed ID: 2433542
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of pimobendan on the clinical outcome and survival of cats with non-taurine responsive dilated cardiomyopathy.
    Hambrook LE; Bennett PF
    J Feline Med Surg; 2012 Apr; 14(4):233-9. PubMed ID: 22412159
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Newer inotropes in pediatric heart failure.
    Hoffman TM
    J Cardiovasc Pharmacol; 2011 Aug; 58(2):121-5. PubMed ID: 21386708
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease.
    Sarcinella F; Neves J; Maddox TW; Hodgkiss-Geere HM; Bode EF; Dukes-McEwan J
    Open Vet J; 2020 Jan; 9(4):375-383. PubMed ID: 32042661
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Levosimendan and pulmonary hypertension.
    Cavusoglu Y; Beyaztas A; Birdane A; Ata N
    J Cardiovasc Med (Hagerstown); 2010 Jul; 11(7):478-80. PubMed ID: 20516805
    [No Abstract]   [Full Text] [Related]  

  • 73. Positive chronotropic and inotropic effects of pimobendan (UD-CG 115 BS) in isolated, cross-circulated canine heart preparations.
    Furukawa Y; Akahane K; Ogiwara Y; Haniuda M; Chiba S
    Arch Int Pharmacodyn Ther; 1989; 300():159-73. PubMed ID: 2575887
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Canine dilated cardiomyopathy: a retrospective study of prognostic findings in 367 clinical cases.
    Martin MW; Stafford Johnson MJ; Strehlau G; King JN
    J Small Anim Pract; 2010 Aug; 51(8):428-36. PubMed ID: 20670255
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Reduction in left ventricular volume and improvement in hemodynamics following intravenous administration of pimobendan (UDGG 115 BS) in dilated cardiomyopathy].
    Permanetter B; Sebening H; Busch U; Lutilsky L
    Z Kardiol; 1990 Aug; 79(8):565-72. PubMed ID: 2220013
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure.
    Sasayama S; Asanoi H; Kihara Y; Yokawa S; Terada Y; Yoshida S; Ejiri M; Horikoshi I
    Heart Vessels; 1994; 9(3):113-20. PubMed ID: 8056717
    [TBL] [Abstract][Full Text] [Related]  

  • 77. An update on treatment and prognostic indicators in canine myxomatous mitral valve disease.
    Häggström J; Höglund K; Borgarelli M
    J Small Anim Pract; 2009 Sep; 50 Suppl 1():25-33. PubMed ID: 19765217
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A pilot study to assess the feasibility of a submaximal exercise test to measure individual response to cardiac medication in dogs with acquired heart failure.
    Ferasin L; Marcora S
    Vet Res Commun; 2007 Aug; 31(6):725-37. PubMed ID: 17253114
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Compounded pimobendan for canine chronic degenerative mitral valve disease and pulmonary hypertension.
    Helms SR; Fox S; Mixon W; Vail J
    Int J Pharm Compd; 2012; 16(1):34-41. PubMed ID: 23050309
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure.
    Hagemeijer F
    Eur Heart J; 1993 Apr; 14(4):551-66. PubMed ID: 8472722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.